Biologic Therapies for Autoimmune and Connective Tissue Diseases

Immunol Allergy Clin North Am. 2017 May;37(2):283-299. doi: 10.1016/j.iac.2017.01.005. Epub 2017 Mar 1.

Abstract

Biologic therapy continues to revolutionize the treatment of autoimmune disease, especially in rheumatology as the pathophysiology of both inflammation and autoimmune disease becomes better understood. These therapies are designed to dampen the response of the inflammatory cascades. Although the first biologic therapies were approved many years ago, expanding indications and new agents continue to challenge the traditional treatment strategies for rheumatic diseases. This article reviews the data supporting the current use of biologic therapies, including off-label indications, in a subset of rheumatic diseases including rheumatoid arthritis, lupus, inflammatory myositis, ankylosing spondylitis, psoriatic arthritis, vasculitis, and gout.

Keywords: Ankylosing spondylitis; Biologic therapy; Gout; Lupus; Psoriatic arthritis; Rheumatoid arthritis.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Psoriatic / immunology
  • Arthritis, Psoriatic / therapy
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / therapy
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / therapy*
  • Biological Products / therapeutic use
  • Biological Therapy* / methods
  • Connective Tissue Diseases / immunology
  • Connective Tissue Diseases / therapy*
  • Gout / therapy
  • Humans
  • Immunologic Factors / therapeutic use
  • Lupus Erythematosus, Systemic / immunology
  • Lupus Erythematosus, Systemic / therapy
  • Spondylitis, Ankylosing / immunology
  • Spondylitis, Ankylosing / therapy
  • Treatment Outcome
  • Vasculitis / immunology
  • Vasculitis / therapy

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Biological Products
  • Immunologic Factors